Qiong Chen Selected Research

Glioblastoma (Glioblastoma Multiforme)

11/2016	The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.
1/2008	LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
1/2008	LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.
10/2007	[Inhibitory effect of LRRC4 on the mobility and invasion of glioblastomas through the SDF-1alpha/CXCR4 axis].
10/2007	Leucine-rich repeat C4 protein is involved in nervous tissue development and neurite outgrowth, and induction of glioma cell differentiation.
11/2006	LRRC4 controls in vitro invasion of glioblastoma cells through inhibiting RPTP-zeta expression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Qiong Chen Research Topics

Disease

45	Neoplasms (Cancer) 04/2024 - 10/2005
17	Inflammation (Inflammations) 04/2024 - 01/2013
17	Adenocarcinoma of Lung 11/2023 - 10/2005
16	Chronic Obstructive Pulmonary Disease (COPD) 04/2024 - 05/2015
14	Lung Neoplasms (Lung Cancer) 01/2021 - 10/2005
11	Neoplasm Metastasis (Metastasis) 04/2024 - 01/2012
11	Infections 01/2023 - 12/2010
10	Hypoxia (Hypoxemia) 03/2024 - 01/2012
10	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 09/2016
9	Carcinogenesis 01/2022 - 01/2008
6	Reperfusion Injury 04/2024 - 07/2008
6	Fibrosis (Cirrhosis) 04/2024 - 01/2011
6	Carcinoma (Carcinomatosis) 09/2023 - 10/2006
6	Stroke (Strokes) 01/2023 - 11/2015
6	Glioblastoma (Glioblastoma Multiforme) 11/2016 - 11/2006
6	Glioma (Gliomas) 11/2016 - 08/2006
5	Ischemic Stroke 03/2024 - 07/2020
5	Birth Weight (Birth Weights) 01/2022 - 09/2014
5	Hemorrhage 12/2021 - 04/2008
5	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2012
4	Asthma (Bronchial Asthma) 04/2024 - 01/2022
4	Hypoglycemia (Reactive Hypoglycemia) 03/2024 - 01/2021
4	Body Weight (Weight, Body) 01/2024 - 05/2012
4	Wounds and Injuries (Trauma) 01/2024 - 06/2010
4	Type 2 Diabetes Mellitus (MODY) 02/2023 - 02/2019
4	Atrial Fibrillation 01/2022 - 01/2019
4	Vascular Remodeling 01/2022 - 01/2015
4	Cerebral Hemorrhage 01/2022 - 01/2020
4	Endometriosis 07/2021 - 02/2013
4	Hepatocellular Carcinoma (Hepatoma) 03/2021 - 02/2008
3	Renal Cell Carcinoma (Grawitz Tumor) 11/2023 - 01/2019
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2023 - 06/2011
3	Brain Injuries (Brain Injury) 01/2022 - 01/2019
3	Lung Injury 09/2021 - 05/2015
3	Emergence Delirium 04/2021 - 01/2020
3	Aortic Dissection 04/2021 - 01/2020
2	Acidosis 03/2024 - 01/2021
2	Hyperplasia 02/2023 - 01/2013
2	Frailty 01/2023 - 01/2023
2	Ischemia 01/2023 - 01/2019
2	Brain Ischemia (Cerebral Ischemia) 01/2023 - 01/2023
2	Tuberculosis (Tuberculoses) 01/2023 - 06/2015
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2022 - 01/2020

Drug/Important Bio-Agent (IBA)

32	Proteins (Proteins, Gene)FDA Link 04/2024 - 10/2005
10	SmokeIBA 04/2024 - 05/2015
10	Messenger RNA (mRNA)IBA 01/2023 - 10/2006
10	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 03/2008
8	RNA (Ribonucleic Acid)IBA 04/2024 - 04/2008
8	Cisplatin (Platino)FDA LinkGeneric 09/2023 - 10/2005
8	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2012
7	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 02/2019
7	Small Interfering RNA (siRNA)IBA 01/2021 - 10/2011
6	Long Noncoding RNAIBA 04/2024 - 08/2017
6	Progesterone FDA LinkGeneric 07/2023 - 05/2013
5	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 01/2012
5	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2015
5	Leucine (L-Leucine)FDA Link 11/2016 - 08/2006
4	6-methyladenineIBA 04/2024 - 01/2021
4	Therapeutic UsesIBA 03/2024 - 01/2013
4	AntioxidantsIBA 07/2022 - 06/2011
4	C-Reactive ProteinIBA 01/2022 - 05/2015
4	Tigecycline (Tygacil)FDA Link 12/2021 - 01/2014
4	Gonadal Steroid Hormones (Sex Hormones)IBA 01/2021 - 05/2013
4	Oxygen (Dioxygen)IBA 07/2020 - 07/2008
4	Adrenal Cortex Hormones (Corticosteroids)IBA 06/2020 - 02/2015
4	CytokinesIBA 01/2020 - 01/2008
4	EnzymesIBA 04/2017 - 08/2011
3	Triggering Receptor Expressed on Myeloid Cells-1IBA 04/2024 - 07/2021
3	salicylhydroxamic acid (SHAM)IBA 01/2023 - 01/2019
3	Neuroprotective AgentsIBA 01/2023 - 08/2011
3	Daptomycin FDA Link 08/2022 - 06/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 01/2020
3	InterleukinsIBA 07/2021 - 01/2017
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 10/2005
3	CateninsIBA 01/2020 - 09/2017
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2018 - 08/2006
3	CollagenIBA 11/2017 - 01/2011
3	Benzo(a)pyreneIBA 10/2017 - 01/2009
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2015 - 01/2008
3	TeaIBA 01/2013 - 08/2008
3	norcantharidinIBA 02/2012 - 01/2011
3	Telomerase (Telomerase Reverse Transcriptase)IBA 10/2011 - 04/2008
3	NF-kappa B (NF-kB)IBA 01/2008 - 08/2006
2	Tumor Biomarkers (Tumor Markers)IBA 03/2024 - 09/2017
2	Carnitine (L-Carnitine)FDA LinkGeneric 03/2024 - 01/2021
2	Immune Checkpoint InhibitorsIBA 09/2023 - 01/2021
2	Recombinases (Recombinase)IBA 06/2023 - 03/2008
2	NucleotidesIBA 03/2023 - 01/2023
2	Peptides (Polypeptides)IBA 02/2023 - 04/2019
2	HLA-G Antigens (HLA G)IBA 01/2023 - 02/2014
2	ChromatinIBA 01/2023 - 01/2022
2	3-n-butylphthalide (butylphthalide)IBA 01/2023 - 01/2020
2	LipopeptidesIBA 08/2022 - 06/2015

Therapy/Procedure

24	Therapeutics 03/2024 - 10/2006
7	Drug Therapy (Chemotherapy) 12/2022 - 10/2005
4	Length of Stay 01/2022 - 06/2010
4	Artificial Respiration (Mechanical Ventilation) 11/2021 - 07/2020
3	Stents 01/2022 - 01/2020
3	Catheter Ablation 01/2020 - 01/2019
2	Immunotherapy 08/2022 - 01/2021